Skip to main content

Table 3 Univariate analysis of preoperative factors associated with unresectability

From: P.R.O.P.S. — A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

  Unresectable (n = 4) Successful (n = 27) P value
Results % (n) % (n)
Clinical presentation
 Bloatedness 75% (3/4) 15% (4/26) 0.03*
 Altered bowel habits 50% (2/4) 12% (3/26) 0.12
 Abdominal pain 50% (2/4) 15% (4/26) 0.17
 Loss of weight 50% (2/4) 8% (2/26) 0.08
 Nausea/vomiting 25% (1/4) 8% (2/26) 0.36
 Abdominal distension 0.0% (0/4) 4% (1/26) 1.00
 Abdominal mass 25% (1/4) 0.0% (0/26) 0.04*
 Pouch of Douglas nodules 0.0% (0/4) 0.0% (0/26)
Disease factor
 High-grade tumour 50% (2/4) 4% (0/27) 0.01*
 Prior neoadjuvant chemotherapy 75% (3/4) 96% (26/27) 0.25
 Neoadjuvant cycles (median months) 9 (3 to 15) 6 (2 to 12) 0.14
 Multiple lines of chemotherapy 50% (1/2) 29% (7/24) 0.04*
 Response to chemotherapy
  Complete response 0.0% (0/3) 76% (16/21)  
   Partial response 67% (2/3) 10% (2/21) 0.11
   No response 0.0% (0/3) 14% (3/21) 0.20
   Progressive disease 33% (1/3) 0.0% (0/21) 0.00*
 Suboptimal resection 25% (1/4) 7% (2/27) 0.04*
 Disease-free interval (median months) 14 (4 to 16) 16 (0 to 62) 0.23
Preoperative investigations
 Elevated tumour markers 100% (4/4) 50% (11/22) 0.03*
 Thrombocytosis 50% (2/4) 15% (4/27) 0.16
 Anaemia 25% (1/4) 41% (11/27) 1.00
 Hypoalbuminemia 50% (2/4) 33% (9/27) 0.60
 CT ascites 100% (4/4) 9% (2/23) 0.00*
 CT omental thickening 100% (4/4) 4% (1/23) 0.00*
 CT lymphadenopathy 25% (1/4) 17% (4/23) 1.00
 CT small bowel disease 25% (1/4) 8% (2/23) 0.01*
  1. *Statistically significant results as P value is less than 0.05